

Index

- Acetylation phenotype, role in occupational health, 85
- Acquired immunodeficiency syndrome (AIDS)
interest in testing workers for, 32, 151-152
testing for, 8, 31, 161
- Addictive disorders, predisposition to, 92
- Adult polycystic kidney disease, 80
- Agency for Toxic Substances and Disease Registry (ATSDR), 109,110,209-210
- Air Force Academy (U.S.), sickle cell and pilot training policy of, 42-43
- Alcoholism, predisposition to, 92
- Allele-specific oligonucleotide (ASO) probes, 78,81
- Allied Chemical & Alkali Workers of American Local No. 1 v. Pittsburgh Plate Glass Co.*, 123
- Alpha-l-antitrypsin
hypersusceptibility due to deficiency in, 41,80
role in occupational health, 86
- American Board of Medical Genetics, 166
- American College of Occupational Medicine, 120, 122, 147
- American Conference of Governmental Industrial Hygienists, 56
- American Hospital Association, 146
- American Medical Association (AMA), Hippocratic oath and, 116, 117, 120, 146
- Americans with Disabilities Act of 1990 (ADA), 16, 114-116, 130, 139, 147, 151
- Ames test, 10,60-61
- Aryl hydrocarbon hydroxylase, cytochrome P-450 and role in occupational health, 86
- Ataxia telangiectasia (AT), role in occupational health, 86-87
- Atherosclerosis, predisposition to, 93-94
- Benzene, elevated CAs in workers exposed to, 65
- Biochemical genetic tests
diagnosis with, 10,77
see *also* Genetic screening
- Biological monitoring, 5,57,60-61
- Blue Cross/Blue Shield, reimbursement for genetic services, 166
- Bureau of Labor Statistics (BLS), 45
- Cancer
bladder, 91-92
chronic myelogenous leukemia (CML), 90
colon, 90-91
detection programs in the workplace, 7,34
DNA adducts and, 67
low-level radiation and, 57-58
lung, 92
oncogenes and, 88, 90-92
retinoblastoma, 90
role of genetics in, 11, 14, 55, 59, 92
tumor suppressor genes and, 90
see *also* Mutagenicity; Mutation; Oncogenes
- Center for Environmental Health & Injury Control—CDC, 209-210
- Centers for Disease Control (CDC), 47,210
- Cetus Corp. (California), 81
- Chemicals
chromosomal abnormalities and, 9,63
cytogenetic surveillance to detect damage by, 9,56
effects on sperm of, 62
health effects compared to radiation, 9,56-57
sister chromatid exchange analysis to detect damage by, 63
types of DNA lesions produced by, 58
- Chernobyl (U.S.S.R.), 57,209
- Cholesterol. See atherosclerosis
- Chromosomal aberrations (CAs)
as a cause of genetic disease, 195-196
chemically induced, 56
elevation in certain worker populations, 65
genetic monitoring to detect, 58,63
radiation induced, 56, 195-196
tests on sperm, 62
use by regulatory agencies to set exposure standards, 66
- Coke oven workers, increase SCE and elevated CAs in, 65
- Collective bargaining
arbitral review, 126
duty to bargain over genetic monitoring and screening, 16, 123-125
NRLA preemption of common law torts, 126
refusals, 125-126
see *also* National Labor Relations Act; National Labor Relations Board
- Company-sponsored health promotion programs. See "Wellness" programs
- Comprehensive Environmental Response, Compensation, and Liability Act, 109
- Confidentiality
American College of Occupational Medicine role in, 120, 122
occupational health physicians role in, 120, 122
of OTA survey, 198
right to, 116-120
State provisions for genetic health care information, 119
- Congress, U.S.
historical interest in genetic monitoring and screening of, 6, 8, 36-37,45
policy issues and options for, 24-29
see *also* House Committee on Energy and Commerce; House Committee on Science and Technology; House Committee on Science, Space, and Technology; Office of Technology Assessment; Senate Committee on Commerce, Science, and Transpor-

- tation
- Constitution (U.S.). See Confidentiality; Legal considerations; Privacy
- Coronary artery disease (CAD), screening for, 162
- Costs. See Economics
- Crick, Francis H. C., 6,41
- Cytochrome P-450, aryl hydrocarbon hydroxylase and role in occupational health, 86
- Cytogenetic tests
- application of, to occupational exposures, 9,65-66
 - appropriateness for use in occupational testing of, 9, 65-66
 - confounders and limitations on analysis using, 9,64
 - industry involvement in, 6, 44-45
- Department of Energy (U.S.), 36,209
- Department of Health and Human Services (U.S.), 209-211
- Department of Health, Education, and Welfare (U.S.), 43
- Department of Labor (U.S.), 45, 197
- Department of Veterans Affairs (U.S.), 211
- Diabetes, predisposition to, 94
- Directory of National Unions and Employees Association, 197
- Discrimination
- American With Disabilities Act of 1990, 16, 114-116
 - associated with sickle cell screening programs, 6, 42
 - Rehabilitation Act of 1973, 15, 113-114
 - Title VII of the Civil Rights Act of 1964, 15-16, 103, 110-111, 126-128, 147
- DNA
- composition and structure of, 3, 191
 - probes, 81
 - variation in sequence of, 78
 - see *also* DNA tests; Genetic tests
- DNA adducts
- genetic monitoring to detect, 58,67-68
 - relationship with cancer, 67
- DNA quantification, carcinogen exposure and, 68
- DNA repair, determination of, and genetic damage, 68
- DNA tests
- automation of, 11, 82-83
 - companies offering diagnostic, 94
 - diagnosis with, 10,80
 - limits of, 83
 - mutation analysis with, 81
 - polymerase chain reaction and, 81-82
- Dow Chemical, 44,45
- Drug testing, interest in use in workplace, 32
- Dun & Bradstreet, 197
- DuPont Corp., 44,45
- Ecogenetics, 83
- Economics
- as justification for genetic monitoring and screening, 6, 46
 - of genetic services, 166
 - of health care costs to business, 5-6, 33
 - of occupational illness, 6,45-46
- Education, employee health risk, 7,34
- Employment-at-will, doctrine of, 14, 126, 127
- Environmental agents, genetic factors affecting susceptibility to, 10-12,83-87
- Environmental Protection Agency (EPA), 46, 50, 65, 109-110,211
- Ethical considerations
- criteria for workplace genetic monitoring and screening programs, 19, 147
 - difference between monitoring and screening, 17, 140-141
 - fair treatment, 17, 147
 - fetal protection policies, 148
 - moral considerations for workers and employers, 141-145
 - privacy, 16-17, 146-147
 - protection of worker health, 151-153
 - social value of work, 142
 - using workplace screening as power, 149
- Ethylene oxide
- monitoring for effects on chromosomes of, 44, 66
- Expenses. See Economics
- Exxon Chemical Americas, 7,34
- Federal Employees Compensation Act, 111
- Federal Government (U. S.)
- agencies involved in occupational safety and health, 46-50
 - workplace safety oversight by, 103-116
 - see *also*, individual agencies and departments
- Fetal protection policies, 128, 148
- Finland, occupational safety and health in, 48
- Florida, law prohibiting genetic discrimination, 17, 42, 130
- Food and Drug Administration (U.S.), 95,210
- Fortune Magazine*, OTA survey population drawn from, 197
- Fourth Amendment rights, 130
- Funding, human genome project research, 8,36-37
- General Motors, 148
- Genetic counseling
- availability and access to services, 20, 165-166
 - conveying genetic risk, 19, 159
 - conveying uncertainty in prognosis through, 19-20, 161-162
 - ethical issues, 18, 140
 - for families, 19, 160-164
 - individual uses of genetic information from 19-20, 157-168
 - informed consent in, 150-160
 - intervention, 19, 161
 - need for sufficient and appropriate, 158-160

- OTA survey of companies using, 166-167
 survey of attitudes toward workplace screening, 18, 144
- Genetic disease
 incidence, 55
 role of environmental agents in, 11, 84
- Genetic monitoring
 battery approach, 70-71
 congressional interest, 6, 36
 considerations for use in workplace, 4, 32-33, 36
 criticisms of, 5-6, 33, 36
 definition and use in OTA report, 3,4,31,55
 detecting mutations with, 9-10,55-56
 distinction from genetic screening, 5-6,32
 ethical considerations of, 17-19, 139-153
 genetic counseling issues of, 19-20, 157-167
 historical perspective, 6,41-45
 in Finland, 48
 legal considerations of, 12-17, 103-134
 methodologic considerations, 10,69-70
 occupational disease and, 3-4,65
 procedural safeguards for and difficulties with, 10,70
 state-of-the-art, 8-10, 55-71
- Genetic screening
 congressional interest, 6, 36
 considerations for use in workplace, 5, 32-33, 36
 criticisms of, 5-6, 33, 36
 definition and use in OTA report, 3,5,31-32,55
 detecting nonoccupationally related disease by, 5, 31-32,87-88,90-94
 detecting occupationally related disease by, 3, 31-32, 83-87
 distinction from genetic monitoring, 5-6,32
 ethical considerations of, 17-19, 139-153
 genetic counseling issues of, 19-20, 157-167
 historical perspective, 6,41-45
 in Finland, 48
 legal considerations of, 12-17, 103-134
 methodologic considerations, 10,69-70
 procedural safeguards for and difficulties with, 10,70
 state-of-the-art, 10-12,77-95
- Genetic services
 availability of and access to, 20, 165-167
 barriers to provision of, 20, 165
 costs of, 166
 see **also** Genetic counseling
- Genetic testing
 definition and use in OTA report, 3,31-32
 methodologic considerations, 10,69-70
 procedural safeguards for and difficulties with, 10,70
 see *also* Genetic monitoring; Genetic screening
- Genetic tests
 availability for certain disorder, 15, 95
 commercial development of, 12, 15,94-95
- Genome. See Human genome project
- Genotoxicity. See Chemicals; Ecogenetics; Mutation;
- Mutagenicity; Radiation
- Glucose-6-phosphate dehydrogenase (G-6-PD)
 deficiency and role in occupational health of, 11,85
 historical perspective and hypersusceptibility of carriers for, 6, 41
- Griggs v. Duke Power Co.*, 110
- Haldane, J.B.S., 6,41
- Hazard Communication Standard, 15, 16, 108
- Health Effects Research Lab-EPA, 211
- Health insurance, costs as justification for genetic monitoring and screening, 5-6,33,46
- Hemoglobinopathies, 192
- High Risk Occupational Disease Notification and Prevention Act, 108-109
- Hippocratic oath, 116, 117, 120
- Hiroshima, Japan, 58,209
- History, genetic monitoring and screening, 6,41-45
 of congressional interest concerning genetics in the workplace, 6, 8, 36-37
- House Committee on Energy and Commerce (U.S.), 3
- House Committee on Science and Technology (U.S.), 3, 6,36
- House Committee on Science, Space, and Technology (U.S.), 3
- Howard Hughes Medical Institute (HHMI), 209
- HPRT Mutational Spectra Repository, 66
- Human genetics. See DNA; Genetic disease; Genetic monitoring; Genetic screening; Genetic testing; Genetic tests
- Human genome project
 impact on screening and monitoring technologies of, 8, 36
 Program Advisory Committee on the Human Genome and ethical issues, 8, 36-37
- Human leukocyte antigen (HLA)
 association with genetic disease, 80-81
 role in occupational health, 87
- Huntington's disease
 psychological considerations and genetic testing for, 20, 163
 survey of attitudes of population at risk for, 20, 163
 test for, 20,92-93
- Hypersusceptibility
 genetic factors and, 84
 historical concept of, 41,50
- Hypoxanthine-guanine phosphoribosyltransferase (HPRT)
 measuring mutation frequencies with gene for, 66
 relationship between mutations, exposures, and cancer, 66
- Industry
 DNA-based diagnostic tests offered by, 94-95
 genetic screening and monitoring involvement by, 6, 44-45
 occupational illness' costs to health insurance, 5, 6,

- 45-46
 1989 OTA survey of, 173-184
- Informed consent
 role of genetic counseling in, 159-160
 State statutes relating to, 160
 see *also* Confidentiality; Privacy
- Institute of Occupational Health, Finland, 48
- Integrated Genetics (Massachusetts), 95
- International Commission for Protection Against Environmental Mutagens and Carcinogens, 65
- International Commission on Radiological Protection, 56
- International United Rubber, Cork, Linoleum, and Plastic Workers of America, 7,34
- Intervention, for genetic disorders
 when it is available, 161
 when it is unavailable, 19-20, 161
- Johnson & Johnson, 44
- Johnson Controls, Inc., 148
- Jones Act, 111
- Kelsey-Seybold Foundation, 7,34
- Korean conflict, military use of antimalarial drug and hypersusceptibility in, 6,41
- Lead standard, 106
- Legal considerations
 collective bargaining, 16, 122-126
 common law right to a safe workplace, 128-129
 confidentiality and privacy, 12, 14, 116-122
 employee rights to know results, 129
 employee rights to refuse monitoring and screening, 129-131
 employment-at-will, 14, 126-127
 Federal responsibility, 15-16, 103-116
 fetal protection policy, 128
 judicial uses of genetic data, 131-133
 liability, 131, 132
 limiting employer testing rights, Fourth Amendment considerations, 130
 State responsibility, 16-17, 111-113, 130
 States explicitly prohibiting genetic discrimination, 17, 130
 use of test results in employment decisions, 12, 126-131
 see *also* Collective bargaining; Confidentiality; Discrimination; Privacy; Workers' compensation
- Legislation
 occupational health and safety oriented, Federal, 15-17, 46-50, 110-111, 113-116, 122-130
 State anti-discrimination, 17,42, 127, 130
 see *also*, individual statutes
- Liability
 of employer for inaccurate results, 131
 other issues, 132
- Linkage analysis, 78,79, 83
 see *also* Restriction fragment length polymorphism
- Longshore and Harbor Workers' Compensation Act, 111
- Louisiana, law prohibiting genetic discrimination, 17,42, 130
- Medical records, access to under OSH Act, 15, 106-107
- Mental disorders, predisposition to, 11,92-93
- Micronuclei assay
 increase in certain worker populations, 54
 limitations using, 65
 relationship to chromosomal aberrations, 64
- Mutagenicity
 analysis at molecular level of, 9-10,66-69
 tests of, 9-10,60-62
 see *also* Chemicals; Mutation; Radiation
- Mutation
 chemical induced, 9,56-57
 DNA adducts and, 10,67-68
 health effects of, 8-10,55-56
 inheritance of, 192-194
 role in cancer, 55,
 see *also* Chemicals; Mutagenicity; Radiation
- Nagasaki, Japan, 58,209
- National Academy of Sciences (NAS)
 report on genetic screening programs, 42
 report on inborn errors of metabolism, 164
 report on sickle cell screening and the armed forces, 42
 see *also* National Research Council
- National Cancer Institute (NCI)
 cancer prevention training and education of workers, 7, 34
 estimate of bladder cancer by, 92
- National Center for Toxicological Research-FDA, 210
- National Institute for Occupational Safety and Health (NIOSH)
 coordination with OSHA, 16,47
 role in genetic monitoring and screening, 47-48, 109, 210
 surveys of workplace safety and health, 49
- National Institute of Environmental Health Sciences, 210, 211
- National Institutes of Health (NIH)
 report on newborn screening for sickle cell, 43
 role in research in genetic monitoring and screening, 210-211
- National Labor Relations Act (NLRA), 16,48-49, 103
- National Labor Relations Board (NLRB), 48-50,122-126
- National Occupational Exposure Survey--(NIOSH), 49
- National Occupational Hazard Survey--(NIOSH), 49
- National Priorities List, 110
- National Radiological Protection Board, United Kingdom, 63
- National Research Council (NRC)
 report on health effects of low levels of radiation, 58

- see *also* National Academy of Sciences
 National Science Foundation, 211-212
 National Sickle Cell Anemia Control Act, 6,36,43
 National Sickle Cell Anemia, Cooley's Anemia, Tay-Sachs, and Genetic Diseases Act, 6,36,43
 National Toxicology Program-DHHS, 209,210,211
 New Jersey, law prohibiting genetic discrimination, 17, 42, 127, 130
 Nixon, President Richard M., 41
 North Carolina, law prohibiting genetic discrimination, 17,42, 130
 Nuclear fuels production
 genetic monitoring of workers at, 57-58
 see *also* Radiation

 Occupational health physicians, legal duties, 14,120,122
 Occupational illness
 as defined by the Department of Labor, 45
 costs, 6,45-46
 ethical considerations of reducing incidence of, 145
 historically, 104
 prevalence, 45
 Occupational and Safety Health Act (OSH Act)
 coverage and duties, 15, 16, 46-47
 general duty clause of, 105
 genetic monitoring and screening under, 15,103, 104, 105-106
 medical and exposure records access, 15-16, 106-107
 medical testing under, 105
 Occupational Safety and Health Administration (OSHA)
 administration of OSH Act by, 47
 cancer prevention and training of workers, 7, 34
 coordination with NIOSH, 16,47
 exposure standards set by, 47
 hazard communication standard of, 15, 108
 policy on genetic monitoring and screening, 16,47
 recordkeeping requirements of, 107-108
 role in genetic monitoring and screening, 16, 103, 104
 see *also* Occupational and Safety Health Act
 Office of Health and Environmental Research-DOE, 209
 Office of Technology Assessment (OTA)
 congressional issues and options identified by, 24-28
 1983 report, 6,8,36,65-66,77,78,83, 85-86,139,171
 report on U.S. investment in biotechnology by, 209
 results of 1986 survey of human genetics by, 171-172
 results of 1988 survey of commercial development of DNA tests by, 165
 scope of 1990 report, 3, 37
 survey of genetic monitoring and screening in the workplace by, 3,20-24,166-167,171-188, 197-200
 Oncogenes
 genetic monitoring and activation of, 58,68-69
 role in cancer of, 88, 90-92
 suppressor genes, 90
 workers exposed to PCBs and activation of, 69

 see *also* Cancer

 Paraoxonase variants, role in occupational health, 87
 Pennzoil Company, cancer detection program used by, 7, 34
 Phenylketonuria, 10,77
 Philadelphia chromosome, 90
 Policy, issues and options for Congress, 24-29
 Polychlorinated biphenyls (PCBs), oncogene activation in workers exposed to, 69
 Polymerase chain reaction (PCR)
 amplification of DNA using, 10-11, 81-82
 genetic screening using, 10-11,91
 Predictive value
 concepts of in genetic testing, 10, 69-70
 of molecularly based tests, 83
 President's Commission for the Study of Ethical Problems in Medicine, Biomedical and Behavioral Research, 164
 Privacy
 ethical considerations of, 17-18, 146-147
 legal considerations of, 14,119-120
 see *also* Privacy
 Protein adducts, 68
 Public Health Service (U. S.) 47

 Radiation
 health effects compared to chemicals, 9,56-57
 low-level, 56-58
 mutagenic effects, 9-10, 56-58
 Ramazzini, Bernardino, 103
 Recordkeeping, OSHA, 107-108
 Rehabilitation Act of 1973, 15, 103, 113-114, 130
 Relative risk, 69
 Reliability
 concepts of in genetic testing, 10, 69-70
 of molecularly based tests, 83
 Research
 role of Federal agencies, 209-212
 role of NIOSH in, 16, 47, 109
 see *also* NIOSH
 Restriction fragment length polymorphisms
 analysis using, 10-11,78-80
 population studies with, 80
 Retinoblastoma, 90

 Schulman, Ronca, & Bucuvalas, Inc., 20, 171, 197, 198
 Senate Committee on Commerce, Science, and Transportation (U.S.), 3
 Serum oncogene proteins, cancer diagnosis and detection of, 68-69
 Sickle cell anemia and trait
 description of, 77, 85
 detection using RFLP analysis of, 81
 frequency of, 77
 hypersusceptibility and, 41

- role in occupational health, 85
- screening programs in the United States for, 6, 41-44
- State laws requiring screening for, 41
- U.S. Air Force Academy pilot training policy, 42-43
- Sister chromatid exchange
 - elevation in certain worker populations, 65
 - genetic monitoring to detect, 58,63-64
 - increase in as a result of chemical exposure, 63
 - use as predictor of health risk, 64
- Southern blotting, 78
- Southern, E.M., 78
- Superfund Amendments and Reauthorization Act (SARA), 109, 110
- Survey
 - attitudes of medical geneticists toward workplace genetic screening, 18, 144
 - attitudes of toward testing of those at risk for Huntington's disease, 20, 163
 - attitudes towards employer use of genetic tests (Lou *Harris-Business Week*), 171-172
 - instruments for OTA, 1982 and 1989, 213-246
 - of companies developing DNA tests, 165
 - of genetic counselors on genetic risk, 160
 - of human genetics offered in U.S. medical schools, 165
 - of public perceptions of human gene manipulation, 162, 171-172
 - methodology, 197-200
 - results of 1982 OTA, 22, 23,201-208
 - results of 1989 OTA, 20-24, 166-167, 171-188
- Tay-Sachs disease
 - screening programs in the United States for, 42, 43
 - use in prenatal diagnosis, 163
- Texas, cancer screening program at Pennzoil facility in, 7, 34
- Thalassemia, role in occupational health, 85
- Three Mile Island (Pennsylvania), 57
- Title VII of the Civil Rights Act, 15, 103, 110-111, 126-128, 130, 147
- Toxic Substances Control Act (TSCA), 61, 109
- United Rubber, Cork, Linoleum, and Plastic Workers of America, 7,34
- validity
 - concepts of in genetic testing, 10-11,69-70
 - of molecularly based tests, 83
- Vinyl chloride, increased CAs in workers exposed to, 65, 66
- Wards Cove Packing v. Atonio*, 15, 110, 111
- Watson, James D., 6,41
- "Wellness" programs
 - genetic screening for nonoccupational disease through, 87-94
 - operation and example of corporate-sponsored, 6-7, 33-35
- Whalen v. Roe*, 119
- Wilson's disease, 79
- Work, social value of, 142
- Workers' compensation
 - admissibility of genetic monitoring and screening data in cases of, 16-17, 113
 - coverage of susceptible employees, 112-113
 - potential for lower costs as justification for genetic monitoring and screening, 6, 32-33,46, 111
 - State role in, 16-17, 111-113
 - test results as evidence in claims for, 17, 113
- World Medical Association, 146